What's on the Horizon for Soft Tissue Sarcoma?

Slides:



Advertisements
Similar presentations
IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)
Advertisements

Introduction  Soft Tissue Sarcoma (STS) are a group of highly chemotherapy resistant tumors  Doxorubicin is the only APPROVED 1 st line chemotherapy.
Targeting Tumors Using Endogenous Albumin
Systemic therapy More recent agents: Unregistered agents:
Randomized phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas (TRS) Sant P. Chawla,
Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.
Clinical Case Nº2 Dr. Javier Martín-Broto. Case description 49-year-old man 1 st symptom/sign: Mild pain in right buttock 1 st diagnosis: Core-biopsy:
Symposium 2: Sarcoma of the Year – Synovial Sarcoma Peter Reichardt HELIOS Klinikum Berlin-Buch / Sarcoma Center Berlin-Brandenburg.
12 th Annual CTOS Meeting 2006 AP23573 Induced Long-term Stability in 2 Patients with Desmoplastic Small Round Cell Tumor (#561) Scott Schuetze, Warren.
The Next Generation of Treatments for Advanced Soft Tissue Sarcomas Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical.
Biology of Sarcomas “The first thing that the general medical oncologist has to realize is that the parallel word to sarcoma is actually carcinoma,
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
The Next Generation of Treatments for Advanced Soft Tissue Sarcomas
© The Author(s) Published by Science and Education Publishing.
Surrogate endpoints in cancer randomized controlled trials:
The Nurse View: Management of Pancreatic Cancer
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
IL-12 and IL-23.
Update on the Diagnosis and Management of CTEPH in Latin America
Non-GIST Soft Tissue Sarcoma: Biology and Basics of Targeted Therapy
Advanced NSCLC Without Actionable Mutations
New Horizons in the Management of Advanced Breast Cancer
The ABCs of AF.
Progressive Fibrosing Interstitial Lung Diseases – Addressing the Challenges Concept of Progressive Fibrosing ILDs With Examples.
Metastatic Renal Cell Carcinoma
Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.
The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer
Advanced Soft Tissue Sarcoma: Current and Future
Program Goals. ESSENTIAL CONCEPTS IN THE USE OF SOMATOSTATIN ANALOGUES IN PATIENTS WITH NEUROENDOCRINE TUMORS.
Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.
Program Goals. The Role of Chemotherapy in Improving Quality of Life in Advanced NSCLC.
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
Metabolically Healthy Patients With Obesity
When Would You Use Single Inhaler Triple Therapy in COPD?
Decision-making in the eRA of Treating to Target
PAH Therapy Revisited.
Updates in Preventing Skeletal-Related Events in Multiple Myeloma
Are We Closer to Personalized Medicine in MS?
How to Optimize TAVR Outcomes
Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.
Opportunities and Challenges in the Management of Advanced STS
Hormone Receptor-Positive Advanced Breast Cancer:
Understanding Comparative Effectiveness Data in Psoriatic Arthritis
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.
Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.
Patient-Centered Management in Pancreatic Cancer
Personalizing Management in the Care of Patients With Advanced Sarcoma
Updates in Heart Failure:
Program Goals Overview Is NEDA a Reasonable Target?
Updates in the Management of Acute Promyelocytic Leukemia
Advances in Immunotherapy for Peanut Allergy
Locally Advanced Lung Cancer
Hormone Receptor-Positive Advanced Breast Cancer Introduction
Pharmacotherapy for Diabetic Coronary Disease:
Treatment of Locally Advanced Pancreatic Cancer
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
New Paradigms in HR-Positive Advanced Breast Cancer
Patient-Centered Management in Advanced Non-Small Cell Lung Cancer
Practical Guidance on the Management of Pan-Negative NSCLC
Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.
The ABCs of AF.
Program Goals Overview Is NEDA a Reasonable Target?
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
MSI.
My PAH Patient.
Understanding the Expanding Armamentarium for GIST
The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Updates in Best Practices in Non-Small Cell Lung Cancer
Uncovering the Right Sequence
Presentation transcript:

What's on the Horizon for Soft Tissue Sarcoma?

Sarcoma Incidence and Mortality

Sarcoma Classification

Survival Data From Sarcoma Trials EORTC 62012

GeDDiS Trial

PICASSO 3 Trial

Key Takeaways From Chemotherapy Trials in Soft Tissue Sarcomas

Targeting PDGF/PDGFR in Sarcoma

Pazopanib

Pazopanib PALETTE Study

Olaratumab (IMC-3G3)*

Doxorubicin ± Olaratumab for Treatment of Advanced STS

Liposarcomas

Leiomyosarcomas

Trabectedin

Trabectedin vs Dacarbazine for Advanced Liposarcoma or Leiomyosarcoma

Eribulin Mesylate

Eribulin vs Dacarbazine for Advanced Liposarcoma or Leiomyosarcoma

Eribulin vs Dacarbazine for Advanced Liposarcoma or Leiomyosarcoma

Palbociclib*

Summary and Conclusions

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.